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Durham,NC; Seoul, SouthKorea;Beijing,China;Uppsala,Mölndal, Sweden; Jakarta, Indonesia; theChineseUniversity
of Hong Kong, Hong Kong; and Cincinnati, OHBackground In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among
patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding. Because Asian patients, when
compared with non-Asian patients, are believed to be more susceptible to bleeding, we evaluated the effects of ticagrelor
compared with clopidogrel in Asian (n = 1,106) and non-Asian (n = 17,515) patients with acute coronary syndrome enrolled
in the PLATO study.
Methods and Results Interaction between Asian/non-Asian and primary efficacy end point (a composite of vascular
death, myocardial infarction, and stroke) and net clinical benefit (composite of primary efficacy end point and coronary artery
bypass graft [CABG] surgery or non–CABG-related major bleeding) were evaluated with a Cox proportional hazards model.
Baseline demographics and comorbidities were different between Asians and non-Asians. The overall cardiovascular event rates
were higher in Asians, but bleeding rates were similar. Despite these observed differences, the effects of ticagrelor versus
clopidogrel were not significantly different between Asians and non-Asians with respect to the primary efficacy outcome (hazard
ratio for Asians vs non-Asians, 0.84 [95%CI 0.61-1.17] vs 0.85 [95%CI 0.77-0.93], P = .974), net clinical benefit (0.85 [95%CI
0.65-1.11] vs 0.93 [95% CI 0.86-0.99], P = .521), or individual efficacy end points. There was no significant interaction for
bleeding (PLATO major bleeding, 1.02 [95% CI 0.70-1.49] vs 1.04 [95% CI 0.95-1.14], P = .938) and other related adverse
events with ticagrelor compared with clopidogrel between Asians and non-Asians.
Conclusions We observed consistency of effects in Asian patients receiving ticagrelor and clopidogrel in the PLATO
study. The relatively modest number of Asian patients in this analysis supports further investigation of larger cohorts to confirm
our observations. (Am Heart J 2015;169:899-905.e1.)t of Internal Medicine,
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cess article under the
nc-nd/4.0/).The direct-acting, potent, fast-acting P2Y12 inhibitor
ticagrelor is recommended for themanagement ofmoderate-
to high-risk patients with acute coronary syndrome (ACS).1,2
Ticagrelor showed superior efficacy compared with
clopidogrel in reducing cardiovascular events andmortality
in the Platelet Inhibition and Patient Outcomes (PLATO)
study, at the expense of an increase in major bleeding not
related to coronary artery bypass graft (CABG) surgery.3
However, generalization of results to individual regions or
specific subgroups is challenging given the diversity of
patients enrolled in this multinational trial.
Asian patients are believed to be susceptible to
antithrombotics or fibrinolytics4,5 and to be associated
with a higher bleeding risk duringmanagement of ischemic
heart diseases and antithrombotic therapy.6,7 There are
concerns about excessive bleeding risk with standard
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June 2015doses of new P2Y12 inhibitors in Asian patients, especially
in East Asian countries.8 For prasugrel, a lower mainte-
nance dose of 3.75 mgdailywas used in clinical studies and
approved for Japanese patients.9,10 The lower bodyweight
of Asian patients, fixed dose regimen of most antiplatelet
drugs, and different genetic backgrounds may explain the
potential for this increased bleeding risk. Thus, bleeding is
viewed as a primary concern for selecting antiplatelet drugs
in Asian patients. A clinical pharmacology study identified
higher drug exposure in Japanese compared with white
subjects participating in a study of single dose and multiple
ascending doses of ticagrelor, adding weight to the general
concern about bleeding in Asian patients.11 However, to
date, clinical outcomes data have been only modest; in
addition, Asian patients with ACS may have different
demographics, comorbidities, and disease patterns com-
pared with white patients with ACS.7,12 Accordingly, we
evaluated the association of race and antiplatelet drugs
(ticagrelor vs clopidogrel) with efficacy and safety
outcomes in a retrospective analysis of PLATO data.
Specifically, our goal was to examine the effects of
ticagrelor versus clopidogrel among Asians and non-Asians
on cardiovascular events, net clinical benefit, and safety
outcomes including bleeding.
Methods
Patients
PLATO was a multinational, multicenter, double-blind,
double-dummy, randomized trial of 18,624 patients
with ST-segment elevation or non–ST-segment elevation
ACS. Details of the study design have been published
previously.3,13 Briefly, patients were randomized to
treatment with clopidogrel or ticagrelor after admission
and within 24 hours of the acute event. Ticagrelor was
administered as a 180-mg loading dose and then as
90 mg twice daily. Clopidogrel was administered with
75 mg once daily after a 300-mg loading dose. The
loading dose of clopidogrel was used only for patients
who had not been receiving clopidogrel for at least
5 days before randomization.
Asian race was investigator identified in the case report
form. Asian race also included races specified as Filipino,
Malay, Bidayuh, or mixed (white and Asian) among “other
races” in the case report form. All remaining patients were
considered to be non-Asian. Patients who lacked sufficient
data for classification as Asian or non-Asian were excluded
from this analysis. Asian patients from Asian regions were
subclassified to East Asian (South Korea, China, or Hong
Kong) and Southeast Asian countries (Thailand, Indonesia,
Malaysia, Singapore, or Philippines) by regional location.
Main outcome measures
The key end points for this analysis were the primary
efficacy outcome and net clinical benefit. The primary
efficacy end point was the composite of death fromvascular causes, myocardial infarction (MI), or stroke.
Secondary efficacy end-points were all-cause death, death
from vascular causes, the composite of vascular death orMI,
stroke, and stent thrombosis defined as probable or definite
by the Academic Research Consortium definition.14 Net
clinical benefit was defined as the composite of death
from vascular causes, MI, stroke, or CABG or non–
CABG-related major bleeding, which incorporated major
bleeding into a major cardiovascular event for evaluation as
a single outcome measure. The safety end points consisted
of bleeding (PLATO-defined major bleeding, non–CABG-
related major bleeding, and fatal bleeding13) and other
safety end points (bradycardia and dyspnea).
Efficacy and net clinical benefit end points were
analyzed based on the intent-to-treat paradigm through
12 months. Bleeding end points were evaluated as
treated and included events that occurred during use of
the study drug or within 7 days after treatment end.
Statistical analyses
Baseline characteristics were presented as medians
(with 25th, 75th percentiles) for continuous variables and
frequencies for categorical variables. Comparisons for
baseline characteristics were made with a t test or
Wilcoxon rank sum test for continuous variables, and a
χ2 or Fisher exact test for categorical variables.
Cox proportional hazards regression assessed outcomes
by race (Asian vs non-Asian). Furthermore, the interaction
between race (Asian vs non-Asian) and antiplatelet
treatment (ticagrelor vs clopidogrel) was assessed using
Cox proportional hazards regression to evaluate whether a
differential treatment effect existed by race.
Among the subgroup of patients living in theAsian region,
we assessed outcomes by subregion (Southeast Asia vs East
Asia) and further evaluated whether a differential treatment
effect existed for Southeast Asian versus East Asian patients
usingmethods similar to those described earlier. All analyses
were performed using SAS, version 9.3 (SAS Institute, Cary,
NC) and P b .05 was considered significant.
Funding
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Results
Baseline characteristics for Asian and non-Asian patients
Of the 18,621 patients included in this analysis from
PLATO, 1,106 patients (5.9%) were reported as being Asian.
Therewere significant differences in baseline characteristics
Table I. Baseline characteristics by race (Asian vs non-Asian) and treatment
Clopidogrel/non-Asian
(n = 8733)
Clopidogrel/Asian
(n = 558)
Ticagrelor/non-Asian
(n = 8784)
Ticagrelor/Asian
(n = 548)
Demographics
Age (y)⁎ 62 (54, 71) 61 (53, 69) 62 (54, 71) 60 (52, 70)
Female 2478 (28.4) 155 (27.8) 2519 (28.7) 136 (24.8)
Weight (kg)⁎ 80 (70, 90) 65 (57, 74) 80 (70, 90) 65 (59, 75)
Body mass index (kg/m2)⁎ 27.6 (24.9, 30.5) 24.2 (22.0, 26.6) 27.6 (25.0, 30.7) 24.3 (22.2, 26.7)
Cardiovascular risk factors
Current smoker 3104 (35.6) 214 (38.4) 3134 (35.7) 226 (41.2)
Diabetes mellitus 2168 (24.8) 168 (30.1) 2169 (24.7) 157 (28.7)
Hypertension 5696 (65.3) 348 (62.4) 5809 (66.2) 330 (60.2)
Dyslipidemia 4146 (47.5) 196 (35.1) 4177 (47.6) 170 (31.0)
Prior disease status
Angina pectoris 3887 (44.5) 251 (45.0) 3976 (45.3) 244 (44.5)
MI 1825 (20.9) 99 (17.7) 1834 (20.9) 66 (12.0)
Congestive heart failure 499 (5.7) 38 (6.8) 489 (5.6) 24 (4.4)
Prior PCI 1179 (13.5) 44 (7.9) 1229 (14.0) 43 (7.9)
Prior CABG 563 (6.5) 11 (2.0) 525 (6.0) 7 (1.3)
Prior TIA 241 (2.8) 12 (2.2) 239 (2.7) 7 (1.3)
Nonhemorrhagic stroke 334 (3.8) 35 (6.3) 317 (3.6) 36 (6.6)
Peripheral artery disease 569 (6.5) 9 (1.6) 562 (6.4) 4 (0.7)
Chronic renal disease 382 (4.4) 24 (4.3) 355 (4.0) 24 (4.4)
Baseline laboratory findings
Hemoglobin A1C (%)⁎ 6.0 (5.7, 6.6) 6.2 (5.7, 7.2) 6.0 (5.6, 6.6) 6.1 (5.7, 7.1)
Creatinine clearance (mL/min)⁎ 80.5 (62.9, 99.0) 74.4 (56.7, 92.4) 80.8 (63.8, 99.5) 76.7 (58.1, 96.0)
Index event
Unstable angina 1474 (16.9) 89 (16.0) 1477 (16.9) 72 (13.1)
Non–ST-segment elevation MI 3754 (43.1) 196 (35.2) 3796 (43.3) 209 (38.1)
ST-segment elevation MI 3277 (37.6) 253 (45.4) 3246 (37.1) 250 (45.6)
Others 211 (2.4) 19 (3.4) 242 (2.8) 17 (3.1)
Concomitant medications
Baseline aspirin use 8162 (93.5) 513 (92.0) 8270 (94.2) 480 (87.6)
Aspirin dose at day 1 (mg)⁎ 100 (75, 100) 100 (75, 100) 100 (75, 100) 100 (100, 150)
ACEi/ARB 5663 (64.9) 360 (64.8) 5735 (65.4) 338 (61.7)
β-Blocker 6321 (72.5) 315 (56.7) 6391 (72.8) 283 (51.6)
Calcium channel blocker 1482 (17.0) 93 (16.7) 1435 (16.4) 80 (14.6)
Statin 6976 (80.0) 413 (74.3) 7026 (80.1) 416 (75.9)
Proton pump inhibitor 3064 (35.1) 191 (34.3) 3089 (35.2) 195 (35.6)
Glycoprotein IIb/IIIa inhibitor 2240 (25.7) 77 (13.9) 2237 (25.5) 61 (11.1)
Planned invasive approach 6246 (71.5) 430 (77.1) 6318 (71.9) 413 (75.4)
Except where indicated, data are presented as n (%).
Abbreviations: PCI, Percutaneous coronary intervention; TIA, transient ischemic attack; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin II receptor blocker.
⁎ Presented as median value with first and third quartiles.
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Volume 169, Number 6between Asian and non-Asian patients (Table I, online
Appendix Supplementary Table). Asian patients were
slightly but significantly younger and had lower body
weight and body mass index than non-Asian patients.
Cardiovascular risk factors were also different between the
2 groups. Although current smoking status and diabetes
mellitus were more common in Asian patients, hyperten-
sion and dyslipidemia were more common in non-Asian
patients. Asian patients less commonly reported a previous
MI or coronary revascularization, but a history of non-
hemorrhagic stroke was more common in Asian patients.
At the time of randomization, the most common type of
ACS event in Asian patients was ST-segment elevation MI,
whereas non–ST-segment elevation MI was more common
in non-Asian patients. Concomitant medication was alsosignificantly different between the 2 groups. In Asian
patients, a lower proportion was treated with aspirin,
β-blocker, statin, and glycoprotein IIb/IIIa inhibitor at
baseline. A higher proportion of Asian patients than
non-Asian patients had a planned invasive strategy.
Outcomes in Asian versus non-Asian patients
Increased risk of the net clinical benefit endpoint (hazard
ratio [HR] 1.19, 95% CI 1.04-1.37, P = .013) and primary
efficacy end point (HR 1.34, 95% CI 1.13-1.59, P = .001)
was observed for the Asian patients compared with
non-Asian. Similar results were observed for other efficacy
end points including stroke and all-cause death. However,
Asian origin was not associated with increased risk of
PLATOmajor bleeding, non–CABG-related major bleeding,
Figure
Interaction of race and treatment in unadjusted Cox models of end points.
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respectively) (online Appendix Supplementary Table).
Among patients meeting the net clinical benefit end point
because of major bleeding under the intent-to-treat para-
digm, 12.8% (161/1,255) of non-Asian and 26.1% (23/88) of
Asian patients subsequently also had a cardiovascular event
(death from vascular cause, MI, or stroke) during the
follow-up period.
Interaction of race and treatment
Figure and Table II show the relationship between
treatment and outcomes by racial group. The reduced risk
of primary efficacy end pointwas consistent betweenAsian
and non-Asian patients (interaction P = .974). The benefits
of ticagrelor compared with clopidogrel were consistent
with net clinical benefit end point, incorporating major
cardiovascular events and major bleeding, between the 2
racial groups (interaction P = .521). Similarly, we did not
observe a differential treatment effect for secondary
efficacy end points including all-cause death (P = .931),
death from vascular causes (P = .792), composite of MI or
vascular death (P = .972), stroke (P = .701), or stent
thrombosis (P = .638). (See Table III.)
Figure also shows that, compared with clopidogrel, the
effect of ticagrelor on the primary safety end point, major
bleeding, was not significantly different between Asian andnon-Asian patients (interaction P = .938). Similar results
were observed for non–CABG-related bleeding and adverse
events including dyspnea and bradycardia (interaction
P = .947, P = .894, and P = .856, respectively).Discussion
In the PLATO study, the primary efficacy end point and
net clinical benefits favored ticagrelor compared with
clopidogrel.3,15 In the present subgroup analysis, the net
clinical benefits of ticagrelor compared with clopidogrel
were not different between Asian and non-Asian patients,
although there were differences in baseline characteris-
tics and cardiovascular event rates between the Asian and
non-Asian. Similarly, there was no significant heteroge-
neity in effects of ticagrelor compared with clopidogrel
on efficacy, bleeding, and other safety end points. The
overall net clinical benefit of ticagrelor was primarily the
result of reduced cardiovascular events, exceeding the
observed increase of major bleeding in both Asian and
non-Asian patients.
Concerns about increased susceptibility of bleeding in
Asian patients compared with non-Asian patients are
supported by lower body weight, differences in genetic
background, comorbidities, and disease patterns of Asian
patients comparedwith white patients as well as the use of
Table II. Net clinical benefit, efficacy end points, and safety end points by race (Asian vs non-Asian) and treatment
Clopidogrel/non-Asian
(n = 8733)
Clopidogrel/Asian
(n = 558)
Ticagrelor/non-Asian
(n = 8784)
Ticagrelor/Asian
(n = 548)
Net clinical benefit 1461 (16.7) 114 (20.4) 1366 (15.6) 96 (17.5)
Efficacy end points
Primary efficacy end point 935 (10.7) 79 (14.2) 798 (9.1) 66 (12.0)
All cause death 454 (5.2) 52 (9.3) 359 (4.1) 40 (7.3)
Death from vascular causes 394 (4.5) 48 (8.6) 317 (3.6) 36 (6.6)
MI 564 (6.5) 35 (6.3) 473 (5.4) 35 (6.4)
Death from vascular causes or MI 869 (10.0) 73 (13.1) 721 (8.2) 60 (11.0)
Stroke 95 (1.1) 11 (2.0) 114 (1.3) 11 (2.0)
Probable or definite stent thrombosis 153 (1.8) 10 (1.8) 112 (1.3) 9 (1.6)
Bleeding end points
PLATO major bleeding 876 (10.1) 53 (9.7) 907 (10.4) 54 (10.0)
Fatal bleeding 21 (0.2) 2 (0.4) 18 (0.2) 2 (0.4)
Non-CABG major bleeding 286 (3.3) 20 (3.6) 338 (3.9) 24 (4.4)
Other safety end points
Dyspnea 684 (7.9) 37 (6.7) 1207 (13.9) 63 (11.6)
Bradycardia 351 (4.1) 21 (3.8) 385 (4.4) 24 (4.4)
Data are presented as n (%). Primary efficacy end point is a composite of death from vascular causes, MI, or stroke.
Table III. Subgroup comparison of outcomes by treatment and countries among Asian patients
Clopidogrel/East
Asian (%)
Clopidogrel/Southeast
Asian (%)
Ticagrelor/East
Asian (%)
Ticagrelor/Southeast
Asian (%)
Net clinical benefit 41/273 (15.0) 56/194 (28.9) 34/278 (12.2) 48/196 (24.5)
Efficacy end points
Primary efficacy end point 28/273 (10.3) 44/194 (22.7) 23/278 (8.3) 34/196 (17.4)
All-cause death 15/273 (5.5) 35/194 (18.0) 10/278 (3.6) 24/196 (12.2)
Death from vascular causes 14/273 (5.1) 32/194 (16.5) 10/278 (3.6) 20/196 (10.2)
MI 14/273 (5.1) 18/194 (9.3) 12/278 (4.3) 18/196 (9.2)
Death from vascular causes or MI 25/273 (9.1) 43/194 (22.1) 21/278 (7.6) 30/196 (15.3)
Stroke 4/273 (1.5) 4/194 (2.1) 2/278 (0.7) 8/196 (4.1)
Probable or definite stent thrombosis 5/273 (1.8) 4/194 (2.1) 4/278 (1.4) 3/196 (1.5)
Bleeding end points
PLATO major bleeding 15/268 (5.6) 27/191 (14.1) 22/276 (8.0) 26/194 (13.4)
Fatal bleeding 0/268 (0.0) 2/191 (1.1) 1/276 (0.4) 1/194 (0.5)
Non-CABG major bleeding 4/268 (1.5) 10/191 (5.2) 11/276 (4.0) 11/194 (5.7)
Other safety end points
Dyspnea 16/268 (6.0) 7/191 (3.7) 37/276 (13.4) 10/194 (5.2)
Bradycardia 9/268 (3.4) 10/191 (5.2) 14/276 (5.1) 4/194 (2.1)
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Volume 169, Number 6single fixed-dose regimens in most antiplatelet and
antithrombotic drugs.7 However, data for bleeding risk
by racial difference are limited, and the bleeding risk in
Asian patients is inconsistent among studies.7,12,16 Com-
pared with clopidogrel, ticagrelor has a direct, potent,
fast-acting P2Y12 inhibition in patients with coronary
artery disease.17,18 Clinical pharmacology studies have
reported higher drug exposure of ticagrelor in Japanese
and Chinese patients and higher levels of inhibition for
platelet aggregation in Japanese patients compared with
whites.11,19 Nevertheless, the effects on bleeding out-
comes defined as PLATO major bleeding, or non-CABG
major bleeding for ticagrelor versus clopidogrel did not
differ between Asian patients and non-Asian patients in the
present study. Although greater platelet inhibition was
associated with higher bleeding risk, the relationshipbetween level of platelet inhibition and bleeding risk is
not straightforward,15,20 and it has not been established
how to estimate risk of major bleeding by level of platelet
inhibition.15,20,21 As shown with race, increased drug
exposure of ticagrelor has been reported for elderly
patients and female patients in clinical pharmacology
studies.11 However, risk of PLATO major bleeding has not
been significantly different according to gender and age in
comparisons of ticagrelor and clopidogrel.3,15
Different genetic predisposition needs to be considered
for evaluation of antiplatelet therapy when clopidogrel is
used as a control. Loss of function alleles of cytochrome
P450 2C19 (CYP2C19) is more common in the Asian
population compared with the non-Asian population22
and is associated with a lower level of platelet inhibition
and an increased risk of ischemic events in clopidogrel
904 Kang et al
American Heart Journal
June 2015users.23,24 Unlike clopidogrel, ticagrelor is not influenced
by CYP2C19 polymorphism.25 The higher prevalence of
loss of CYP2C19 function polymorphism in Asian patients
may favor ticagrelor compared with clopidogrel in terms
of platelet inhibition and may be related to the observed
reduction in ischemic events. However, in terms of
bleeding risk, presence of CYP2C19 loss of function
alleles may be associated with a reduced risk of bleeding
events in patients treated with clopidogrel.6,25
Bleeding is known to be associated with increased risk
of cardiovascular events.26 In the present analysis, a
higher cardiovascular event rate was observed in both
Asian and non-Asian patients who experienced major
bleeding compared with patients without bleeding.
However, susceptibility of subsequent cardiovascular
event after major bleeding might be different between
Asian and non-Asian patients. Numerically higher subse-
quent ischemic events were observed in Asian patients
who experienced major bleeding than in those without
bleeding. This finding needs further evaluation and
confirmation in future studies. The reason why Asian
patients were more susceptible to subsequent cardiovas-
cular events after a major bleeding is unclear. The risk
factors associated with major bleeding may have a greater
association with risk factors of cardiovascular event, or
differences in practice patterns, or comorbidities may
influence the subsequent cardiovascular events. The
preconceived idea that Asian patients are prone to higher
risk of bleeding may result in more frequent discontinua-
tion of study drugs or antithrombotic drugs in Asian
patients. In the context of frequent use of percutaneous
coronary intervention in high-risk patients with ACS,
outcomes of premature or inappropriate discontinuation
of antithrombotic drug could be detrimental.
This study was limited in that it was a retrospective
analysis of the PLATO study. There was a relatively modest
number of Asian patients included in our analysis, and the
population was heterogeneous. Defining Asian patients is
difficult for many reasons. To minimize the extent of
heterogeneity, we prespecified exclusion of patients from
the Indian subcontinent. Accordingly, our studypopulation
best reflects patients from East and Southeast Asia.
Nevertheless, to the best of our knowledge, this represents
the largest study cohort to date of Asian patients receiving
ticagrelor in the setting of ACS.
There were significant differences in demographics,
risk factors, comorbidities, disease pattern, and use of
treatments between Asian and non-Asian patients.
Nevertheless, the effects of ticagrelor compared with
clopidogrel on net clinical benefit, ischemic events,
bleeding, and adverse reactions were consistent in Asian
patients compared with non-Asian patients in this
analysis. In Asian patients, risk of major bleeding
associated with ticagrelor compared with clopidogrel
did not exceed the benefits from reduction in cardiovas-
cular events in this analysis.Acknowledgements
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Volume 169, Number 6AppendixSupplementary Table. Baseline characteristics
Total (n = 18621) Non-Asian (n = 17515) Asian (n = 1106) P
Demographics
Age (y)⁎ 62 (54, 71) 62 (54, 71) 61 (52, 69) b.001
Female 5288 (28.4) 4997 (28.5) 291 (26.3) .113
Weight (kg)⁎ 80 (70, 90) 80 (70, 90) 65 (58, 75) b.001
Body mass index (kg/m2)⁎ 27.4 (24.7, 30.5) 27.6 (24.9, 30.6) 24.2 (22.1, 26.6) b.001
Cardiovascular risk factors
Current smoker 6678 (35.9) 6238 (35.6) 440 (39.8) .005
Diabetes mellitus 4662 (25.1) 4337 (24.8) 325 (29.4) .001
Hypertension 12183 (65.5) 11505 (65.7) 678 (61.3) .003
Dyslipidemia 8689 (46.7) 8323 (47.5) 366 (33.1) b.001
Prior disease status
Angina pectoris 8358 (44.9) 7863 (44.9) 495 (44.8) .919
MI 3824 (20.5) 3659 (20.9) 165 (14.9) b.001
Congestive heart failure 1050 (5.6) 988 (5.6) 62 (5.6) .958
Prior PCI 2492 (13.4) 2405 (13.7) 87 (7.9) b.001
Prior CABG 1106 (5.9) 1088 (6.2) 18 (1.6) b.001
Prior TIA 499 (2.7) 480 (2.7) 19 (1.7) .041
Non-hemorrhagic stroke 722 (3.9) 651 (3.7) 71 (6.4) b.001
Peripheral artery disease 1144 (6.2) 1131 (6.5) 13 (1.2) b.001
Chronic renal disease 785 (4.2) 737 (4.2) 48 (4.3) .834
Baseline laboratory findings
Hemoglobin A1C (%)⁎ 6.0 (5.7, 6.6) 6.0 (5.6, 6.6) 6.1 (5.7, 7.2) b.001
Creatinine clearance (mL/min)⁎ 80.3 (63.0, 98.9) 80.6 (63.3, 99.2) 75.0 (57.8, 93.6) b.001
Index event b.001
Unstable angina 3112 (16.8) 2951 (16.9) 161 (14.6)
Non–ST-segment elevation MI 7955 (42.8) 7550 (43.2) 405 (36.7)
ST-segment elevation MI 7026 (37.8) 6523 (37.3) 503 (45.5)
Others 489 (2.6) 453 (2.6) 36 (3.3)
Concomitant medications
Baseline aspirin use 17425 (93.6) 16432 (93.8) 993 (89.8) b.001
Aspirin dose at day 1 (mg)⁎ 100 (75, 100) 100 (75, 100) 100 (100, 150) b.001
ACEi/ARB 12098 (65.0) 11400 (65.2) 698 (63.2) .191
β-Blocker 13310 (71.6) 12712 (72.7) 598 (54.2) b.001
Calcium channel blocker 3090 (16.6) 2917 (16.7) 173 (15.7) .386
Statin 14831 (79.7) 14002 (80.0) 829 (75.1) b.001
Proton pump inhibitor 6539 (35.2) 6153 (35.2) 386 (34.1) .890
Glycoprotein IIb/IIIa inhibitor 4615 (24.8) 4477 (25.6) 138 (12.5) b.001
Planned invasive approach 13407 (72.0) 12564 (71.7) 843 (76.2) .001
Except where indicated, data are presented as n (%).
Abbreviations: MI, Myocardial infarction PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transient ischemic attack; ACEi/ARB, angiotensin
converting enzyme inhibitor/angiotensin II receptor blocker.
⁎ Presented as median value with first and third quartiles.
